Physician profile
Suma S Thomas
NPI 1407272206
$3,766.87
in general payments reported to CMS, 2019-2025
27 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,987 · 2020: $234 · 2021: $940 · 2022: $387 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $676.96 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $623.21 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $514.31 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $470.37 | 2019-2025 | Zepbound |
| Novo Nordisk INC | $235.23 | 2019-2022 | |
| Pfizer INC. | $154.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $137.62 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $131.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $123.79 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $108.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $80.35 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.28 | 2019 | |
| Bioventus LLC | $55.29 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $49.78 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.09 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.83 | 2019 | |
| Abbvie INC. | $41.53 | 2022 | |
| Ibsa Pharma INC. | $34.43 | 2021 | |
| Currax Pharmaceuticals LLC | $29.58 | 2021-2022 | |
| Allergan, INC. | $28.52 | 2020 | |
| Aspira Women'S Health INC | $23.13 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.60 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.20 | 2019 | |
| Myovant Sciences INC. | $12.70 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.69 | 2019 | |
| Shire North American Group INC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suma Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.